Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The validations confirm the completion of the applications and commence the scientific review process
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
Subscribe To Our Newsletter & Stay Updated
